MABCAMPATH 30mg / ml perfusive solution concentrate medication leaflet

L01XC04 • alemtuzumab • Antineoplastic and immunomodulating agents | Other antineoplastic agents | Monoclonal antibodies

Alemtuzumab is a monoclonal antibody used for the treatment of relapsing multiple sclerosis and chronic lymphocytic leukemia (CLL). It works by targeting the CD52 protein on the surface of lymphocytes, destroying cells involved in autoimmune or cancerous responses.

It is administered via intravenous infusion, usually in cycles, under the supervision of a specialist. Alemtuzumab is commonly used in patients who do not respond to other treatments or have severe forms of the disease.

Side effects may include infusion reactions, infections, fever, fatigue, or autoimmune disorders. In rare cases, severe reactions such as kidney damage or opportunistic infections may occur.

Patients should be closely monitored before, during, and after treatment to identify any adverse reactions. It is essential to follow the doctor's recommendations to minimize risks and optimize treatment benefits.